Other

Matrx Therapeutics Corporation

Jerome Owen Cantor

Bronislava Shteyngart

Charles R Ashby, Jr

Gerard M Turino

Sandra Eve Reznik

The subject invention is directed to the treatment of inflammatory disorders by administration of N,N-dimethylacetamide and its mono-methylated metabolites. The compounds are useful in the management or treatment of inflammatory disorders, such as generative inflammation associated preterm labor and premature rupture of membranes leading to preterm birth.

Administration of N,N-dimethylacetamide for the treatment of preterm birth

The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid.

Compositions and methods for treating elastic fiber breakdown

The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.

Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders

The subject invention is directed to the measurement of elastic fiber breakdown products in human sputum obtained from patients with emphysema and other lung diseases. Measurement of elastic fiber breakdown products may be used to monitor the progression of lung disease or to assess the efficacy of a treatment for lung disease. Such breakdown products are associated with lung injury resulting from degradation of lung elastic fibers. This process may occur in emphysema and other inflammatory disease of the lung where excess amounts of elastase are secreted by inflammatory cells. The methods for measuring elastin breakdown products in certain tissue fluids (i.e. blood, urine, bronchoalveolar lavage fluid) are well known to the art but have not been previously applied to sputum samples. The use of sputum has several advantages over other fluids, including greater specificity and ease of procurement.

Measurement of elastic fiber breakdown products in sputum

The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.

Lectins as anti-fibrotic agents

The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme. Respiratory disorders include emphysema, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of lysozyme may be performed by aerosol, which can be generated by a nebulizer or by instillation. The lysozyme may be administered alone or with a carrier such as saline solution, DMSO, and alcohol, or water. It may also be used as a vehicle for the intratracheal administration of drugs or other agents to the lung. The lysozyme may be isolated from a natural source, such as eggs, or synthesized by a bioprocess, such as fermentation. The effective daily amount of lysozyme is from about 10 &mgr;g/kg to about 1 mg/kg of body weight.

Intratracheal administration of lysozyme

The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of hyaluronic acid. Respiratory disorders include emphysema, chronic bronchitis, asthma, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, and pulmonary atelectasis. The treatment is intended for a variety of mammals, such as premature neonates to adult humans. Administration of hyaluronic acid may be performed by aerosol, which can be generated by a nebulizer, or by instillation. The hyaluronic acid may be administered alone, or with a carrier such as saline solution, DMSO, an alcohol or water. It may be isolated from a natural source such as a bovine or rooster. The effective daily amount of hyaluronic acid is from about 10 .mu.g/kg to about 1 mg/kg of body weight.

Growing community of inventors

Brooklyn, NY, United States of America

Jerome Owen Cantor